SPRB

Spruce Biosciences Inc

44.55

Nov 02 • 3:59 PM ET -1.84 (-3.97%)

44.55

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: RARE DNLI RGNX BMRN PLX ABEO RCKT LXEO DSGN PASG

| Held by: VTI IWM VXF IWN VTWO IWC IWO QQQS VTWV RSSL

Scroll to Statements

Index	RUT
Market Cap	128.04M
Enterprise Value	39.41M
Income	-51.35M
Sales	0.00M
Book/sh	30.42
Cash/sh	33.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Oct 09, 2020

P/E	-
Forward P/E	49.68
PEG	1.20
P/S	-
P/B	1.46
P/C	1.33
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.23
Current Ratio	9.23
Debt/Eq	0.09
LT Debt/Eq	0.06
Option/Short	No / Yes

EPS (ttm)	-40.87
EPS next Y	0.90
EPS next Q	-5.68
EPS this Y	49.35%
EPS next Y	103.48%
EPS next 5Y	41.25%
EPS past 3/5Y	29.85% 11.80%
Sales past 3/5Y	- -
EPS Y/Y TTM	52.43%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-90.92%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-15.37% -

Insider Own	12.62%
Insider Trans	0.00%
Inst Own	66.89%
Inst Trans	39.81%
ROA	-82.38%
ROE	-105.98%
ROIC	-57.98%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.41%
SMA50	-10.67%
SMA200	-19.91%
Trades

Shs Outstand	2.75M
Shs Float	2.51M
Short Float	20.80%
Short Ratio	6.43
Short Interest	0.52M
52W High	129.00 -65.47%
52W Low	38.06 17.05%
Volatility	5.97% 6.37%
ATR (14)	2.79
RSI (14)	47.17
Beta	3.62
Rel Volume	1.11
Avg Volume	81.25K
Volume	90,551

Perf Week	1.27%
Perf Month	-2.54%
Perf Quarter	-3.70%
Perf Half Y	-24.96%
Perf YTD	-48.86%
Perf Year	-59.54%
Perf 3Y	-46.96%
Perf 5Y	-87.33%
Perf 10Y	-
Recom	1.00
Target Price	148.00
Prev Close	46.39
Price	44.55
Change %	-3.97%

Consensus

Strong Buy

Avg. Price Target

$148.00

Implied Upside

+232.2%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 17, 2026	Initiated	LLake Street	Buy	$149	+234.5%
Jul 13, 2026	Initiated	RB. Riley Securities	Buy	$160	+259.1%
Jun 16, 2026	Initiated	GGuggenheim	Buy	$123	+176.1%
Apr 27, 2026	Initiated	CCraig Hallum	Buy	$140	+214.3%
Dec 23, 2025	Initiated	OOppenheimer	Outperform	$283	+535.2%
Dec 03, 2025	Upgrade	LLeerink Partners	Market Perform → Outperform	$160	+259.1%
Oct 28, 2025	Upgrade	CCitizens JMP	Mkt Perform → Mkt Outperform	$254	+470.1%

Today 04:05PM	Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference (Business Wire)
Oct-15-26 04:05PM	Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference (Business Wire) +6.39%
Oct-08-26 04:05PM	Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting (Business Wire)
Sep-08-26 04:05PM	Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire) -5.67%
Aug-27-26 08:09AM	Spruce Biosciences stock gains after analyst backs regulatory progress (InvestorsHub)
08:00AM	Loading…
Aug-26-26 08:00AM	Spruce Biosciences Announces Launch of MPS3BStudy.com (Business Wire)
Aug-24-26 08:00AM	Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 (Business Wire) +13.71%
Aug-12-26 09:00AM	Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (Business Wire)
08:00AM	Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences (Business Wire)
Aug-03-26 08:00AM	Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development (Business Wire)
Jul-27-26 08:00AM	Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer (Business Wire)
Jul-13-26 09:41AM	American Express, Biogen upgraded: Wall Street's top analyst calls (The Fly)
Jul-08-26 04:01PM	Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit (Business Wire)
Jun-29-26 08:00AM	Spruce Biosciences Joins the Russell 3000 Index (Business Wire)
Jun-22-26 08:00AM	Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs (Business Wire)
08:00AM	Loading…
Jun-15-26 08:00AM	Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller (Business Wire)
Jun-09-26 09:32AM	Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls (The Fly)
Jun-08-26 04:05PM	Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium (Business Wire)
May-28-26 04:05PM	Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium (Business Wire)
May-27-26 04:05PM	Spruce Biosciences to Participate in Upcoming Conferences in June (Business Wire)
May-13-26 08:00AM	Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates (Business Wire)
May-04-26 08:00AM	Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations (Business Wire)
Apr-20-26 11:45PM	Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -26.05%
04:01PM	Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Apr-03-26 08:00PM	Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade (Quartz)
Mar-09-26 07:05AM	Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates (Business Wire) +11.17%
07:00AM	Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer (Business Wire)
Mar-03-26 10:20AM	Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway (Insider Monkey)
Mar-02-26 04:05PM	Spruce Biosciences to Present at Upcoming Investor Conferences in March (Business Wire)
Mar-01-26 05:37PM	Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference (MarketBeat)
07:00AM	Loading…
Feb-18-26 07:00AM	Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -8.18%
Feb-17-26 04:05PM	Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire) -12.14%
Feb-05-26 04:05PM	Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -10.58%
Feb-03-26 08:00AM	Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team (Business Wire) +7.05%
Jan-28-26 08:00AM	Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium (Business Wire)
Jan-21-26 07:24AM	Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences (Benzinga) +10.44%
Jan-18-26 07:02PM	Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration (PR Newswire)
Jan-08-26 08:00AM	Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital (Business Wire) -5.62%
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-15-25 08:00AM	Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors (Business Wire)
Nov-10-25 04:05PM	Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (Business Wire) -8.97%
Oct-15-25 12:00PM	What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? (Zacks) -10.09%
Oct-08-25 08:00AM	Spruce Biosciences Announces $50.0 Million Private Placement Financing (Business Wire) -12.34%
Oct-07-25 09:44AM	This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. (Barrons.com) +40.03%
Oct-06-25 05:04PM	Why Spruce Biosciences Just Skyrocketed Almost 1,400% (Investor's Business Daily) +1,378.46%
08:00AM	Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
Sep-15-25 07:00AM	Spruce Biosciences Resumes Trading on the Nasdaq Capital Market (Business Wire) -20.97%

Show Previous News

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Ways Douglas Kirk	Interim Chief Medical Officer	Dec 11 '25	Option Exercise	1,250	1,250	Jan 21 04:04 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 15 '25	Option Exercise	1,009	8,447	Dec 17 04:58 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 15 '25	Option Exercise	2,676	14,922	Dec 17 04:56 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 11 '25	Option Exercise	1,900	8,296	Dec 12 07:05 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 10 '25	Option Exercise	514	6,580	Dec 12 07:05 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 11 '25	Option Exercise	4,950	15,192	Dec 12 07:03 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 10 '25	Option Exercise	1,196	10,670	Dec 12 07:03 PM

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Executive ChairmanMr. Michael G. Grey

M.P.H.Dr. Javier Szwarcberg M.D.

M.B.A.Mr. Samir M. Gharib CPA

Vice President of MarketingMr. Eric Jordan M.B.A.

M.Sc.Mr. Bruno Gagnon BPHARM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRB

Spruce Biosciences Inc

Upgrade your Finviz experience